Business Wire

Calvin McDonald Joins The Wella Company as CEO

11.2.2026 14:30:00 CET | Business Wire | Press Release

Share

The Wella Company, an innovative global beauty leader, today announced that Calvin McDonald has been chosen as the company’s next Chief Executive Officer, effective April 2, 2026. Calvin will also be appointed to the company’s Board of Directors and will be based in New York. Glenn Murphy will remain as Executive Chair to provide continuity as well as strategic advice to the new CEO and the leadership team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210093439/en/

Calvin McDonald

“We are delighted to welcome Calvin to The Wella Company,” said Glenn Murphy, Executive Chair. “As a three-time CEO, he brings decades of experience at industry-leading global consumer brands and retail businesses. Calvin’s proven ability to drive results through product differentiation, category expansion, and smart investments will help us win in the dynamic beauty sector.”

Under KKR’s ownership, The Wella Company has been transformed into a global powerhouse of iconic brands that both professionals and consumers trust. The company's robust brand portfolio includes Wella Professionals—the #1 salon color brand globally*, Sebastian Professional, OPI, ghd, Nioxin, and Clairol. Over the past few years, the team has further elevated the brands, refined the innovation pipeline, and built a solid foundation for long-term sustainable growth.

“We are pleased with the growth that Wella has achieved since our initial investment and are confident that Calvin is the right leader to build on that foundation and propel the company into its next chapter,” said Nancy Ford, Partner at KKR. “We thank Glenn for his leadership of The Wella Company and look forward to working with him in his new capacity, alongside Calvin and the broader leadership team as they continue to further Wella’s success and reach in the beauty sector globally.”

“I’m thrilled to return to the beauty industry—an innovative, fast evolving sector powered by consumers who are genuinely passionate about the products they love,” said Calvin McDonald.

Calvin is a recognized leader across multiple portions of the consumer space. As President and CEO of Sephora Americas, a division of the LVMH group of luxury brands, Calvin oversaw five consecutive years of double-digit growth, transformed Sephora into a market leader in the Americas, and grew haircare into the company’s fastest-growing category. He built a strong foundation for innovation, positioning Sephora as an industry pioneer with the ability to anticipate trends and incubate brands to meet evolving consumer needs. Calvin most recently served as CEO of lululemon athletica inc., where he guided the company through a period of significant growth and innovation, more than tripled annual revenues, and broadened global reach to over 30 geographies.

“I’m energized by the opportunity to use my experience to help elevate these iconic brands, partner with the pros who bring them to life, and unlock new ways to connect with consumers,” continued McDonald. “This is a pivotal moment for The Wella Company, and I’m excited to join this talented team as we shape the future of beauty together.”

Calvin is a member of the Board of Directors of The Walt Disney Company. He holds an MBA from the Rotman School of Management at the University of Toronto and a Bachelor of Science degree from the University of Western Ontario.

About Calvin McDonald

Calvin McDonald is a growth-oriented leader with a proven track record of helping large organizations scale, innovate, and elevate customer engagement in stores and across digital channels. In his most recent role as Chief Executive Officer at lululemon athletica inc., Mr. McDonald drove significant growth, tripling the company’s annual revenues over seven years, broadening its global reach to over 30 countries, and expanding the product portfolio to include new athletic and lifestyle categories such as tennis and golf.

Prior to joining lululemon in August 2018, Mr. McDonald served for five years as president and CEO of Sephora Americas, a division of the LVMH group of luxury brands, driving five consecutive years of double-digit growth and turning haircare into the company’s fastest-growing category. Earlier in his career, he held multiple senior roles across some of Canada’s largest retailers, including 17 years at Loblaw Companies Limited.

He earned his MBA from the University of Toronto and Bachelor of Science degree from the University of Western Ontario. Born and raised in Canada, Mr. McDonald is an endurance athlete who frequently competes in ironman distance triathlons and marathons. He and his wife enjoy spending time with their four children.

Mr. McDonald serves on the Board of Directors of The Walt Disney Company.

About The Wella Company

The Wella Company is an innovative global beauty leader with a strategically integrated portfolio of iconic, time-tested hair, nail, and beauty tech brands. The company's robust brand portfolio including Wella Professionals—the #1 salon color brand globally*—along with Sebastian Professional, OPI, ghd, Nioxin, and Clairol, empowers professional hair and nail artists and beauty-loving consumers worldwide.

Built on 145 years of creating legendary beauty, The Wella Company operates through a powerful, digitally led distribution network that reaches customers globally across professional salons, premium retail, mass retail, and eCommerce channels. The company's fusion of science, technology, and artistry produces performance-led products, often distinguished by patented technology and professional expertise.

Working as a connected, diverse global community of 6,000+ employees, we have a shared desire to positively impact the communities we serve. The Wella Company has a performance-based culture, an enduring entrepreneurial spirit, and a compelling vision to enable individuals to look, feel, and be their true selves. The company has primary offices in New York City, Geneva, London, and Calabasas, California.

*Based on Wella Master Brand USD sales on the 2024 Salon Hair Care Global Series for the hair coloring products category published by Kline

View source version on businesswire.com: https://www.businesswire.com/news/home/20260210093439/en/

Contacts

Media Contacts

Alix Dunn
Alix.Dunn@wella.com

FGS Global
wellacompany@fgsglobal.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye